{"nctId":"NCT01806623","briefTitle":"The Study Of Fluconazole For Vulvovaginal Candidiasis","startDateStruct":{"date":"2013-03-05","type":"ACTUAL"},"conditions":["Vulvovaginal Candidiasis"],"count":157,"armGroups":[{"label":"Fluconazole","type":"EXPERIMENTAL","interventionNames":["Drug: Fluconazole"]}],"interventions":[{"name":"Fluconazole","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients with clinical symptoms and signs of vulvovaginal candidiasis.\n* Patients tested positive for Candida by fungal culture.\n* Patients who can agree not to have intercourse up to 28 days after dosing.\n\nExclusion Criteria:\n\n* Patients with a history of hypersensitivity to fluconazole.\n* Patients with severe renal dysfunction.\n* Patients with liver disorder.","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Therapeutic Outcome: Response Rate","description":"Therapeutic outcome was determined by combination of clinical efficacy and mycological efficacy for each participant as Effective, Ineffective or Indeterminate. The therapeutic outcome was considered as Effective when the clinical efficacy was Cure and the mycological efficacy was Eradication.\n\nPrimary evaluation of therapeutic outcome was on Day 28.\n\nResponse rate was calculated based on the following formula, \"the number of participants assessed as effective\" over \"total participants excluding ones assessed as indeterminate\" multiplied by 100.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"54.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"74.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Clinical Efficacy: Cure Rate","description":"Scores of severity in signs and symptoms at each observation dates were compared with those before the treatment and the clinical efficacy was determined as Cure (the clinical symptom disappeared), Improvement (the clinical symptom was improved: the total score of clinical symptom was reduced relative to the total score before the treatment), Failure (the criteria for Cure and Improvement were not met, or other systemic antifungal drugs or local antifungal drugs were administered for the treatment of the disease to be examined) or Indeterminate (efficacy for each item was not determined for the reasons including failure to conduct the test, or other systemic antifungal agents or local antifungal drugs were administered for the treatment of infections other than the disease to be examined).\n\nCure rate was calculated based on the following formula, \"the number of participants assessed as Cure\" over \"total participants excluding ones assessed as Indeterminate\" multiplied by 100.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"57.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"81.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Clinical Efficacy: Cure and Improvement Rate","description":"Scores of severity in signs and symptoms on each observation dates are compared with those before the treatment and the clinical efficacy is determined as Cure (the clinical symptom disappeared), Improvement (the clinical symptom was improved), Failure (the criteria for Cure and Improvement were not met, or other systemic antifungal drugs or local antifungal drugs were administered for the treatment of the disease to be examined) or Indeterminate (efficacy for each item was not determined for the reasons including failure to conduct the test, or other systemic antifungal agents or local antifungal drugs were administered for the treatment of infections other than the disease to be examined).\n\nCure and improvement rate was calculated based on the following formula, \"the number of participants assessed as Cure or Improvement\" over \"total participants excluding ones assessed as Indeterminate\" multiplied by 100.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Mycological Efficacy: Eradication Rate","description":"Determined based on the results of culture of Candida as Eradication, Persistent or Indeterminate.\n\nEradication rate was calculated based on the following formula, \"the number of participants assessed as Eradication\" over \"total participants excluding ones assessed as Indeterminate\" multiplied by 100.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"95.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"89.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"85.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Total Scores for Clinical Symptoms","description":"Sum of severity scores in vulvovaginal itching, vulvovaginal burning sensation, excoriation of vulva, vaginal discharge, vulva oedema, redness of vulva, vaginal redness, property of vaginal content. Higher scores show greater severity. Total Scores for Clinical Symptoms Severity range from 0 (best possible outcome) to 24 (worst possible outcome).","paramType":"MEAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Maximum Observed Plasma Concentration (Cmax)","description":null,"paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.71","spread":"24"}]}]}]},{"type":"SECONDARY","title":"Time to Reach Maximum Observed Plasma Concentration (Tmax)","description":null,"paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Area Under the Plasma Curve From Time Zero to Last Quantifiable Concentration (AUClast)","description":"Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast)","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"156.1","spread":"22"}]}]}]},{"type":"SECONDARY","title":"Maximum Observed Concentration (Cmax) for Vaginal Fluid Fluconazole Concentration Adjusted by Sample Weight","description":null,"paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.33","spread":"49"}]}]}]},{"type":"SECONDARY","title":"Time to Reach Maximum Observed Concentration (Tmax) for Vaginal Fluid Fluconazole Concentration Adjusted by Sample Weight","description":null,"paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for Vaginal Fluid Fluconazole Concentration Adjusted by Sample Weight","description":"Area under the concentration time-curve from zero to the last measured concentration (AUClast) for Vaginal Fluid Fluconazole Concentration adjusted by Sample Weight","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"79.5","spread":"43"}]}]}]},{"type":"SECONDARY","title":"Maximum Observed Concentration (Cmax) for Vaginal Fluid Fluconazole Concentration Adjusted by Potassium in Vaginal Fluid","description":null,"paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.53","spread":"59"}]}]}]},{"type":"SECONDARY","title":"Time to Reach Maximum Observed Concentration (Tmax) for Vaginal Fluid Fluconazole Concentration Adjusted by Potassium in Vaginal Fluid","description":null,"paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for Vaginal Fluid Fluconazole Concentration Adjusted by Potassium in Vaginal Fluid","description":"Area under the concentration time-curve from zero to the last measured concentration (AUClast) for Vaginal Fluid Fluconazole Concentration Adjusted by Potassium in Vaginal Fluid","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"85.3","spread":"48"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":157},"commonTop":["Nasopharyngitis","Cystitis","Genital herpes","Eczema","Diarrhoea"]}}}